D-0123-2024 Class II Ongoing

Recalled by Glenmark Pharmaceuticals Inc., USA — Mahwah, NJ

FDA drug recall D-0123-2024 was initiated by Glenmark Pharmaceuticals Inc., USA on Nov 7, 2023 and is designated Class II. Reason for recall: Labeling: Label Mix-Up-Indomethacin bottles may be labeled as Naproxen The recall status is ongoing. Affected quantity: 37,200 bottles.

Recall details

Product Type
Drugs
Report Date
Dec 6, 2023
Initiation Date
Nov 7, 2023
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
37,200 bottles

Product description

Indomethacin 25mg Capsules, USP, 100-count bottle, Rx Only, Manufactured by: Glenmark Pharmaceuticals Ltd. Colvale-Bardez, Goa 403513, India, Manufactured for: Glenmark Pharmaceuticals Inc., USA Mahwah, NJ 07430, NDC 68462-406-01

Reason for recall

Labeling: Label Mix-Up-Indomethacin bottles may be labeled as Naproxen

Distribution pattern

Nationwide

Code information

Lot# 19231903; Exp 4/2025 Lot# 19231858; Exp 4/2025 Lot# 19231881; Exp 4/2025 Lot# 19233484; Exp 8/2025 Lot# 19233490; Exp 8/2025

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0123-2024
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0123-2024. Report a data issue: hello@regdatalab.com.